Vaccibody.com | Management
123
page,page-id-123,page-parent,page-template-default,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-9.5,wpb-js-composer js-comp-ver-4.12,vc_responsive

Management

Vaccibody, a unique and innovative Vaccine Platform able to deliver intelligent vaccines for human and veterinary use.

Martin Bonde BW (00000002)

Dr. Bonde has more than 25 years of international experience from the biotech industry.

Martin Bonde

Chief Executive Officer

Martin Bonde joined Vaccibody in August 2015. He holds a Ph.D. in Immunochemical Techniques and a Master of Science in Chemical Engineering from the Technical University of Denmark as well as a Bachelor of Commerce in International Economy from Copenhagen Business School.

 

Dr Bonde started his career in Dako AS, followed by Ostemeter AS (CEO), Torsana Biosensor AS (CEO), Celtor Biosystems Inc (EVP), Combio AS (CEO), Natimmune AS (CEO), Aros Pharma ApS (CEO) and most recently Epitherapeutics Aps now sold to Gilead (CEO).  His experience includes a significant number of transactions within business development, trade sales, mergers & acquisitions as well as management of research and development.

 

 

IMG_2802-3

Agnete B. Fredriksen, Chief Scientific Officer. Ph.D, is one of the inventors of the Vaccibody technology.

Agnete B. Fredriksen

Chief Scientific Officer

Agnete B. Fredriksen joined Vaccibody as Chief Scientific Officer in 2007. She holds a M.Sc., Ph.D.  from Institute of Immunology, University of Oslo, Rikshospitalet Medical Center, Oslo where she designed and developed the first Vaccibodies.

 

Previous employments include Researcher at Affitech AS, Oslo and Medinnova AS. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies.

IMG_2727-2

Mona Welschof, Chief Clinical Officer, Ph.D, has extensive experience in clinical development.

Mona Welschof

Chief Clinical Officer

Mona Welschof joined Vaccibody in October 2013. She earned her PhD in the field of
recombinant antibody technology from the University of Heidelberg/German Cancer
Research Center (DKFZ) in Heidelberg in 1997.

 

Mona Welschof has extensive experience in all phases of clinical drug development from early stage to registration. She comes from a position as Clinical Director of PCI Biotech. Prior to this she held various management
positions in Biopharmaceutical Companies/CROs (Photocure, Affitech AS, Inovio AS and Quintiles).